Brighton Jones’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$255K Sell
6,722
-523
-7% -$24.1K ﹤0.01% 1135
2026
Q2
$347K Buy
7,245
+1,088
+18% +$46.7K 0.01% 974
2026
Q1
$226K Buy
+6,157
New +$292K 0.01% 1040
2025
Q4
– Sell
-13,976
Closed -$776K – 654
2025
Q3
$776K Sell
13,976
-130
-0.9% -$7.61K 0.02% 475
2025
Q2
$974K Buy
14,106
+343
+2% +$23.3K 0.03% 332
2025
Q1
$956K Sell
13,763
-374
-3% -$30.9K 0.03% 272
2024
Q4
$1.22M Sell
14,137
-1,039
-7% -$112K 0.04% 227
2024
Q3
$1.81M Buy
15,176
+606
+4% +$80.8K 0.07% 143
2024
Q2
$2.08M Buy
14,570
+5,625
+63% +$745K 0.07% 148
2024
Q1
$1.15M Buy
8,945
+1,134
+15% +$135K 0.04% 204
2023
Q4
$808K Buy
7,811
+501
+7% +$49.5K 0.03% 236
2023
Q3
$665K Buy
7,310
+1,500
+26% +$132K 0.03% 237
2023
Q2
$470K Buy
5,810
+508
+10% +$41.5K 0.02% 306
2023
Q1
$422K Buy
5,302
+66
+1% +$4.68K 0.02% 316
2022
Q4
$354K Sell
5,236
-268
-5% -$15.7K 0.02% 304
2022
Q3
$274K Buy
5,504
+848
+18% +$45.4K 0.02% 353
2022
Q2
$259K Buy
4,656
+68
+1% +$3.77K 0.02% 360
2022
Q1
$255K Buy
4,588
+74
+2% +$3.8K 0.01% 413
2021
Q4
$253K Buy
+4,514
New +$245K 0.01% 425
2018
Q4
– Sell
-10,060
Closed -$237K – 280
2018
Q3
$237K Buy
+10,060
New +$246K 0.03% 238

Other funds holding NVO

Brighton Jones's NVO Position: Q3 2026 in Review

Brighton Jones reduced its Novo Nordisk (NVO) stake by 7.2% in Q3 2026, selling an estimated $24.1K and leaving 6,722 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #1135.

Brighton Jones first reported a position in NVO in Q3 2018 and has held it in 20 quarters since. The position peaked at $2.08M in Q2 2024. 1,093 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • Brighton Jones held 6,722 shares of Novo Nordisk worth $255K as of Q3 2026.
  • Brighton Jones sold 523 Novo Nordisk shares in Q3 2026, an estimated $24.1K.
  • Novo Nordisk made up ﹤0.01% of Brighton Jones's portfolio in Q3 2026, its #1135 holding.
  • Brighton Jones first reported a position in Novo Nordisk in Q3 2018 and has held it in 20 quarters since.
  • Brighton Jones's Novo Nordisk position peaked at $2.08M in Q2 2024.
  • 1,093 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on Brighton Jones's 13F filing for Q3 2026, filed 3 Nov 2026.